Oncology Today with Dr Neil Love

Ovarian Cancer — Microlearning Activity 4: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Ovarian Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Prostate Cancer — An Interview with Prof Karim Fizazi

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 4

Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 3

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

CD20 x CD3 bispecific antibodies offer transformative, durable responses for patients with relapsed or refractory non-Hodgkin lymphoma, including those who have failed CAR T-cell therapy. Clinical management centers on the prompt recognition and mitigation of cytokine release syndrome (CRS), which typically occurs duri...

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

PD-1/VEGF bispecific antibodies, specifically ivonescimab, represent a transformative approach in managing non-small cell lung cancer by simultaneously targeting checkpoint inhibition and angiogenesis. Clinical data from trials like HARMONi-6 and HARMONi-A demonstrate that this dual-targeting strategy significantly imp...

Chronic Lymphocytic Leukemia — Microlearning Activity 2

Management of relapsed or refractory Chronic Lymphocytic Leukemia (CLL) centers on optimizing treatment sequences and integrating novel therapies. The Bruin CLL 322 trial establishes the triplet regimen of pirtobrutinib, venetoclax, and rituximab as a superior alternative to the standard venetoclax-rituximab doublet, p...

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Optimal management of Chronic Lymphocytic Leukemia (CLL) requires balancing treatment efficacy with patient quality of life and long-term toxicity. Dr. Catherine Coombs of UCI Health highlights that delaying obinutuzumab administration in AVO triplets improves tolerability while maintaining high undetectable MRD rates,...

Ovarian Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 4 with Dr Sara M Tolaney

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Advanced lung cancer management is shifting toward complex combination regimens and targeted antibody-drug conjugates (ADCs). For EGFR-mutated non-small cell lung cancer, combination therapies like amivantamab plus lazertinib are increasingly preferred over monotherapy to improve progression-free survival, despite dist...

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer